Financial Reports Latest Updates Industry Maps Economic Calendar

ENANTA PHARMACEUTICALS INC (ENTA) Annual Reports

Q: Where can I read ENANTA PHARMACEUTICALS INC (ENTA) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

ENANTA PHARMACEUTICALS INC is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 09/30
SEC CIK： 1177648 →

Website：Official site ↗

Financial Highlights

FY2026 Q3 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$14.4M	$18.3M	-21.6%
Operating income	$-17.2M	$-18.9M	+8.8%
Net income	$-19.5M	$-18.3M	-6.8%
EPS (diluted)	$-0.67	$-0.85	+21.2%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 14.4 mn Net income -19.5 mn

Periods follow the company’s fiscal year (Apple ends in September, Walmart in January), so they differ from calendar quarters.

Show table：Income statement

Item	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2	2026Q3
Revenue	41.9	0.74	36.6	2.54	1.86	27.9	1.20	1.65	1.35	0.89	2.16	42.0	2.64	77.5	57.4	11.6	14.4	48.5	13.0	14.0	12.8	10.4	8.96	7.51	75.9	38.1	44.0	57.3	67.2	69.9	39.6	44.4	51.3	52.6	27.6	18.6	23.6	31.7	20.1	21.6	23.6	27.6	18.7	19.5	20.3	23.6	17.8	18.9	18.9	18.0	17.1	18.0	14.6	17.0	14.9	18.3	15.1	18.6	17.2	14.4
Operating income	25.3	—	32.1	-3.53	-4.10	21.9	-4.00	-4.18	-4.70	-5.46	-5.13	34.9	-5.33	70.2	48.6	1.70	3.67	35.6	-0.56	-1.09	-3.10	-7.05	-9.51	-13.1	54.3	14.4	16.9	22.6	34.5	27.9	-1.30	3.76	6.43	12.9	-11.9	-22.9	-19.8	-12.3	-29.7	-33.9	-33.7	-30.4	-33.9	-32.5	-27.1	-30.0	-39.5	-36.7	-31.0	-34.9	-32.8	-24.2	-29.9	-23.5	-24.5	-18.9	-18.4	-11.3	-11.8	-17.2
Net income	23.3	-3.16	32.1	-3.50	-4.05	22.0	-3.75	-4.14	-4.44	-5.37	-5.20	50.0	-5.04	42.0	28.8	2.42	5.81	26.2	-1.64	-1.08	-1.80	-4.98	-5.39	-8.43	36.5	11.7	12.6	20.3	27.4	26.0	4.14	7.04	9.19	13.4	-6.00	-14.3	-29.3	-8.33	-22.0	-24.0	-24.6	-30.1	-33.6	-31.7	-26.4	-29.0	-37.7	-39.1	-28.1	-33.4	-31.2	-22.7	-28.8	-22.3	-22.6	-18.3	-18.7	-11.9	-13.1	-19.5

Balance sheet

Quarterly · In mn (USD)

Total assets 297 mn Total liabilities 196 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2	2026Q3
Current assets	—	—	—	—	47.3	—	112	97.9	105	94.4	99.3	112	108	185	178	173	171	209	243	242	232	224	191	206	238	248	306	340	380	423	424	451	402	441	403	413	437	446	428	321	319	327	342	313	312	284	271	448	423	390	351	287	300	268	243	223	204	199	178	204
Total assets	—	—	—	—	52.2	—	126	120	117	110	108	160	155	215	246	238	246	278	282	282	281	278	279	276	327	341	355	379	414	454	462	473	490	511	514	512	486	481	468	450	439	441	407	385	375	348	326	495	462	429	414	399	377	349	323	301	281	330	315	297
Current liabilities	—	—	—	—	5.73	—	4.95	2.94	4.53	2.57	4.42	4.27	4.75	19.9	19.8	7.31	6.70	10.9	12.0	9.57	7.89	6.43	9.15	11.1	21.0	19.2	17.1	14.0	16.0	22.6	20.5	20.5	22.6	19.1	19.5	23.9	24.2	23.0	26.6	28.6	36.2	37.9	30.7	23.0	29.8	23.0	32.2	68.2	62.8	62.4	54.6	58.2	57.5	49.0	46.0	44.5	48.6	44.7	46.4	54.2
Total liabilities	—	—	—	—	8.23	—	7.25	5.26	6.51	4.58	6.63	6.56	6.76	21.7	21.7	9.49	9.86	14.1	15.2	12.9	11.3	10.2	12.9	15.0	25.0	23.1	21.3	18.2	20.6	27.4	25.4	25.4	27.3	28.7	27.5	31.1	30.6	29.0	31.7	32.6	39.4	56.2	48.2	47.2	54.1	46.7	57.1	257	246	237	247	250	248	237	229	222	216	203	198	196
Equity	-132	—	—	—	-115	—	118	114	110	106	102	153	149	194	224	228	236	264	266	269	270	268	266	261	302	318	333	361	394	427	436	448	462	482	486	481	456	452	436	418	399	384	359	338	321	301	269	238	217	192	166	149	129	112	93.5	79.3	64.7	127	117	101

Cash flow

Quarterly · In mn (USD)

Operating -9.97 mn Investing 14.0 mn Financing -5.54 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2	2026Q3
Operating	24.0	—	28.1	-3.83	-1.70	9.05	10.0	-5.92	-2.50	-5.87	-4.13	35.1	-4.93	-5.61	98.9	-14.2	-2.37	30.0	10.1	-2.11	-2.13	3.15	-3.00	-4.80	57.3	4.41	-7.58	4.05	28.3	30.3	30.1	2.53	8.55	12.4	14.7	-4.49	-15.5	-14.9	-4.58	-29.5	-21.0	-13.3	-26.4	-29.6	-15.5	-35.6	-13.8	-32.1	-21.6	-25.0	-28.6	-14.8	-10.4	-16.8	-13.5	17.5	-6.49	-11.7	-7.16	-9.97
Investing	-17.7	—	-14.4	-12.9	9.24	2.50	-15.9	-48.2	-7.64	1.35	17.3	-27.3	9.21	7.03	-107	8.17	4.10	-5.63	-0.46	-31.4	-6.15	0.87	1.81	7.66	-14.9	-2.45	6.46	-31.5	-7.95	-20.9	1.32	-14.8	-52.2	-37.2	27.8	26.8	2.50	-17.4	25.5	-43.7	72.7	45.5	-35.0	16.2	28.2	33.6	46.8	-146	11.8	-13.1	58.6	-6.34	19.1	68.9	-4.37	-26.5	2.30	-47.3	11.9	14.0
Financing	0.03	—	0.11	-0.02	-0.99	-1.32	59.5	-1.44	0.12	0.09	0.56	0.47	0.04	2.01	0.25	0.12	0.16	0.15	0.53	1.97	0.06	0.03	-0.21	0.19	1.01	0.42	-0.01	2.97	1.03	1.14	0.26	0.49	0.69	1.17	4.36	3.23	0.23	0.3	1.15	0.69	0.94	9.63	3.35	4.12	2.93	0.3	-2.03	200	-0.02	-7.35	-6.41	-6.65	-7.21	-4.99	-6.89	-6.42	-8.32	64.1	-7.29	-5.54
Cash at period end	6.84	—	20.7	3.96	10.5	20.7	74.5	18.9	8.86	4.43	18.1	26.4	30.7	34.1	25.8	19.8	21.7	46.2	56.4	24.8	16.6	20.6	19.2	22.3	65.7	68.0	66.9	42.5	63.9	74.4	106	94.2	51.2	27.6	74.3	99.9	87.1	55.1	77.1	4.60	57.2	99.1	41.0	28.4	44.0	42.2	73.2	95.2	85.4	39.9	63.5	35.8	37.2	84.3	60.2	44.8	32.3	37.4	34.9	33.4

Profitability

Quarterly · %

Operating margin -120.0% Net margin -135.8%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2	2026Q3
Operating margin	60.4%	—	87.8%	-138.8%	-220.4%	78.6%	-334.5%	-253.4%	-348.5%	-611.1%	-237.4%	83.0%	-202.0%	90.6%	84.7%	14.7%	25.5%	73.5%	-4.3%	-7.8%	-24.1%	-67.6%	-106.1%	-174.8%	71.5%	37.7%	38.3%	39.5%	51.3%	39.9%	-3.3%	8.5%	12.5%	24.5%	-43.0%	-122.5%	-83.7%	-38.8%	-147.5%	-156.5%	-143.1%	-110.0%	-180.8%	-167.1%	-133.1%	-127.3%	-221.7%	-194.3%	-163.9%	-193.8%	-192.1%	-134.6%	-204.4%	-138.8%	-164.3%	-103.2%	-121.6%	-60.5%	-69.1%	-120.0%
Net margin	55.7%	-426.3%	87.8%	-137.7%	-218.1%	78.8%	-313.5%	-250.9%	-329.4%	-601.3%	-240.9%	119.0%	-191.2%	54.2%	50.1%	20.9%	40.3%	54.1%	-12.7%	-7.7%	-14.0%	-47.8%	-60.2%	-112.2%	48.1%	30.7%	28.5%	35.4%	40.8%	37.2%	10.5%	15.9%	17.9%	25.6%	-21.7%	-76.5%	-124.2%	-26.2%	-109.5%	-111.1%	-104.3%	-108.9%	-179.5%	-162.7%	-129.7%	-122.9%	-211.6%	-206.8%	-148.5%	-185.6%	-182.7%	-126.1%	-197.3%	-131.4%	-151.7%	-99.7%	-123.6%	-64.1%	-76.3%	-135.8%

Returns & leverage

Quarterly · %

ROE -70.1% ROA -21.1% Debt ratio 66.0%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2	2026Q3
ROE	—	—	—	—	—	—	9.0%	8.8%	—	-16.8%	-17.4%	26.2%	26.6%	54.7%	71.0%	35.8%	41.0%	27.6%	13.4%	11.8%	8.6%	-3.6%	-5.0%	-7.8%	6.2%	11.7%	17.5%	26.1%	20.7%	23.2%	20.2%	16.0%	10.8%	7.4%	5.1%	0.5%	-7.9%	-12.4%	-16.1%	-18.6%	-18.5%	-24.1%	-28.3%	-31.8%	-33.8%	-35.2%	-39.7%	-45.9%	-49.7%	-56.1%	-60.5%	-59.6%	-67.2%	-69.1%	-74.3%	-80.6%	-84.6%	-60.0%	-59.0%	-70.1%
ROA	—	—	—	—	41.0%	—	8.5%	8.4%	11.4%	-16.1%	-16.4%	25.1%	25.3%	50.3%	65.4%	34.3%	39.4%	25.6%	12.4%	11.3%	8.2%	-3.4%	-4.7%	-7.4%	5.8%	11.1%	16.5%	24.8%	19.4%	21.7%	19.1%	15.2%	10.3%	7.0%	4.8%	0.5%	-7.4%	-11.7%	-15.1%	-17.4%	-17.1%	-21.9%	-25.7%	-28.7%	-29.9%	-30.6%	-34.0%	-30.0%	-31.9%	-35.6%	-35.6%	-25.8%	-27.7%	-27.0%	-26.2%	-26.3%	-24.9%	-21.1%	-19.4%	-21.1%
Debt ratio	—	—	—	—	15.8%	—	5.8%	4.4%	5.6%	4.2%	6.1%	4.1%	4.3%	10.1%	8.8%	4.0%	4.0%	5.1%	5.4%	4.6%	4.0%	3.7%	4.6%	5.4%	7.6%	6.8%	6.0%	4.8%	5.0%	6.0%	5.5%	5.4%	5.6%	5.6%	5.4%	6.1%	6.3%	6.0%	6.8%	7.2%	9.0%	12.8%	11.9%	12.3%	14.4%	13.4%	17.5%	52.0%	53.1%	55.2%	59.8%	62.7%	65.8%	67.9%	71.0%	73.7%	77.0%	61.6%	63.0%	66.0%

EPS

Quarterly · US$

EPS US$-0.67

Show table：EPS

Item	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q1	2013Q2	2013Q3	2013Q4	2014Q1	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2	2026Q3
EPS（US$）	1.32	-4.44	2.17	-4.31	-4.78	1.45	-2.28	-0.23	-0.25	-0.30	-0.28	2.61	-0.27	2.18	1.49	0.13	0.29	1.36	-0.09	-0.06	-0.09	-0.26	-0.28	-0.44	1.86	0.59	0.61	0.97	1.30	1.25	0.20	0.33	0.44	0.65	-0.30	-0.71	-1.46	-0.41	-1.09	-1.19	-1.22	-1.48	-1.63	-1.53	-1.27	-1.39	-1.79	-1.86	-1.33	-1.58	-1.47	-1.07	-1.36	-1.05	-1.06	-0.85	-0.88	-0.42	-0.45	-0.67

Revenue & profit

Year-to-date · In mn (USD)

Revenue 50.1 mn Net income -44.5 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 297 mn Total liabilities 196 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -28.8 mn Investing -21.4 mn Financing 51.3 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin -80.5% Net margin -88.8%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -70.1% ROA -21.1% Debt ratio 66.0%

EPS

Year-to-date · US$

EPS US$-1.54

Revenue & profit

Annual · In mn (USD)

Revenue 65.3 mn Net income -81.9 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	41.7	32.0	47.7	161	88.3	103	207	205	122	97.1	86.2	79.2	67.6	65.3
Operating income	—	9.03	19.0	124	30.8	24.6	88.3	36.7	-41.6	-110	-124	-137	-122	-85.3
Net income	21.4	9.63	34.4	79.0	21.7	17.7	72.0	46.4	-36.2	-79.0	-122	-134	-116	-81.9

Balance sheet

Annual · In mn (USD)

Total assets 281 mn Total liabilities 216 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	47.3	105	108	171	232	238	380	402	437	319	312	423	300	204
Total assets	52.2	117	155	246	281	327	414	490	486	439	375	462	377	281
Current liabilities	5.73	4.53	4.75	6.70	7.89	21.0	16.0	22.6	24.2	36.2	29.8	62.8	57.5	48.6
Total liabilities	8.23	6.51	6.76	9.86	11.3	25.0	20.6	27.3	30.6	39.4	54.1	246	248	216
Equity	-115	110	149	236	270	302	394	462	456	399	321	217	129	64.7

Cash flow

Annual · In mn (USD)

Operating -19.3 mn Investing 40.4 mn Financing -26.6 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	—	10.7	20.2	76.7	35.8	52.6	29.2	71.4	7.09	-70.0	-84.8	-103	-78.8	-19.3
Investing	—	-69.2	0.5	-88.2	-43.7	-4.57	-35.4	-86.7	19.8	37.0	54.9	-53.6	58.2	40.4
Financing	—	56.9	1.16	2.54	2.71	1.02	4.41	2.57	8.98	3.08	20.0	198	-27.6	-26.6
Cash at period end	10.5	8.86	30.7	21.7	16.6	65.7	63.9	51.2	87.1	57.2	44.0	85.4	37.2	32.3

Profitability

Annual · %

Operating margin -130.7% Net margin -125.4%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating margin	—	28.2%	39.8%	77.2%	34.9%	23.9%	42.8%	17.9%	-34.0%	-112.9%	-143.7%	-173.2%	-179.9%	-130.7%
Net margin	51.3%	30.0%	72.1%	49.1%	24.6%	17.2%	34.8%	22.6%	-29.5%	-81.4%	-141.3%	-168.9%	-171.6%	-125.4%

Returns & leverage

Annual · %

ROE -84.6% ROA -24.9% Debt ratio 77.0%

Show table：Returns & leverage

Item	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	—	—	26.6%	41.0%	8.6%	6.2%	20.7%	10.8%	-7.9%	-18.5%	-33.8%	-49.7%	-67.2%	-84.6%
ROA	41.0%	11.4%	25.3%	39.4%	8.2%	5.8%	19.4%	10.3%	-7.4%	-17.1%	-29.9%	-31.9%	-27.7%	-24.9%
Debt ratio	15.8%	5.6%	4.3%	4.0%	4.0%	7.6%	5.0%	5.6%	6.3%	9.0%	14.4%	53.1%	65.8%	77.0%

EPS

Annual · US$

EPS US$-3.84

Show table：EPS

Item	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	-11.36	-1.31	1.76	4.09	1.12	0.88	3.47	2.22	-1.82	-3.91	-5.91	-6.37	-5.48	-3.84

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read ENANTA PHARMACEUTICALS INC (ENTA) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.